RCMI Coordinating Center (RCMI CC) Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
Francia, Giulio
One or more keywords matched the following items that are connected to Francia, Giulio
Item TypeName
Academic Article Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.
Academic Article Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts.
Academic Article Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Academic Article Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
Academic Article Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1.
Academic Article Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Academic Article Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
Academic Article Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
Academic Article Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
Academic Article Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.
Academic Article Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice.
Concept Xenograft Model Antitumor Assays
Academic Article Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Academic Article Raising the bar for cancer therapy models.
Academic Article Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.
Search Criteria
  • Xenograft Model Antitumor Assays
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support